Skip to main content
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · AUPH ISIN · CA05156V1022 LEI · 5299008YP2BW4570ML28 US Manufacturing
Open in API
Filings indexed 582 across all filing types
Latest filing 2016-07-11 Regulatory Filings
Country CA Canada
Listing US AUPH

About Aurinia Pharmaceuticals Inc.

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering therapies for patients with severe autoimmune diseases that have high unmet medical needs. The company's principal product is LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus. Aurinia's research and development efforts are centered on immunomodulating therapies for various autoimmune and kidney-related diseases.

Recent filings

Filing Released Lang Actions
AURINIA PHARMACEUTICALS INC. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules. The content includes a news release about the appointment of a Head of Communications & Advocacy. The document length is 2087 characters, which is relatively short and primarily contains an announcement rather than detailed financial data or comprehensive reports. Form 6-K filings typically serve as regulatory filings for foreign issuers to disclose material information. There is no indication of financial statements, audit reports, or detailed management discussion. Therefore, this document fits best under Regulatory Filings (RNS) as it is a general regulatory announcement without substantive financial or operational report content.
2016-07-11 English
SCHEDULE 13D
Major Shareholding Notification
2016-07-05 English
REPORT OF FOREIGN PRIVATE ISSUER DATED JUNE 30, 2016
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed pursuant to SEC rules. It is dated June 30, 2016, and includes a signature from the CFO. The content is brief (2052 characters) and primarily serves as a report filing rather than a full financial report or detailed disclosure. Form 6-K filings typically provide updates or material information between annual reports for foreign issuers. Given the short length and nature of the document, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-06-30 English
AURINIA PHARMACEUTICALS INC. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules under the Securities Exchange Act of 1934. Form 6-K filings are typically used by foreign companies to report material information that is not required to be filed on Forms 20-F or 40-F (annual reports). The document includes a news release about clinical study results but does not contain comprehensive financial statements or detailed financial analysis. The length is short (2147 characters), and it is a regulatory submission providing current information rather than a full report. Therefore, this document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2016-06-29 English
AURINIA PHARMACEUTICALS INC. 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules. The content includes a news release about the closing of a US$7 million private placement. The document length is 2080 characters, which is relatively short and primarily serves as an announcement rather than a detailed financial report. The key content is about a financing event (private placement), which aligns with capital or financing updates. Given the nature of the document as a Form 6-K and the content about a private placement closing, the most appropriate classification is Capital/Financing Update (CAP).
2016-06-22 English
AURINIA PHARMACEUTICALS INC. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes a news release about a private placement, indicating a financing activity update. The document length is short (2056 characters) and primarily serves as a regulatory filing to disclose this information. It does not contain detailed financial statements or comprehensive report content. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a full financial report or capital/financing update report type.
2016-06-15 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.